Obesity is associated with in vivo platelet activation and impaired responsiveness to once-daily, low-dose aspirin

Journal of Thrombosis and Haemostasis

9 Aprile Apr 2019 15 days ago
  • Cavalca V, Porro B, Tremoli E

Obesity is raising worldwide, increases cardiovascular risk, modifies body composition and organ function, and potentially affects drug's pharmacokinetics and/or pharmacodynamics. Aim of this paper was to investigate pharmacodynamics of once-daily low-dose aspirin in healthy obese subjects and to assess whether body weight (BW) or body mass index (BMI) would affect aspirin pharmacology.

Reference

Petrucci G, Zaccardi F, Giaretta A, Cavalca V, Capristo E, Cardillo C, Pitocco D, Porro B, Schinzari F, Toffolo G, Tremoli E, Rocca B. Obesity is associated with in vivo platelet activation and impaired responsiveness to once-daily, low-dose aspirin. J Thromb Haemost 2019 Apr 1. doi: 10.1111/jth.14445. [Epub ahead of print]

Go to PubMed